Research progress in radiotherapy combined with immunotherapy for non-small cell lung cancer
Yuan Meng, Men Yu, Hui Zhouguang
Department of Radiation Oncology (Yuan M),Department of VIP Medical Services (Men Y,Hui ZG),National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract：Radiotherapy is the common traditional treatment for non-small cell lung cancer (NSCLC). In recent years, remarkable advances have been made in immunotherapy, especially the use of immune checkpoint inhibitors. How to effectively combine radiotherapy and immunotherapy to maximize the benefit for patients has become a hot topic in clinical research. This article expounds recent research progress in immunotherapy for NSCLC, the effect of radiotherapy on tumor immunology, and the advances and challenges in radiotherapy combined with immunotherapy for NSCLC.
Yuan Meng,Men Yu,Hui Zhouguang. Research progress in radiotherapy combined with immunotherapy for non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(5): 533-537.
[1]Wakelee H,Kelly K,Edelman MJ.50 years of progress in the systemic therapy of non-small cell lung cancer[J].Am Soc Clin Oncol Educ Book,2014,34(1):177-189.DOI:10.14694/EdBook_AM.2014.34.177. [2]Mccarthy F,Roshani R,Steele J,et al. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC)[J].J Leukoc Biol,2013,94(6):1201-1206.DOI:10.1189/jlb.0313121. [3]Zhao M,Li H,Li L,et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients[J].Exp Ther Med,2014,7(5):1403-1407.DOI:10.3892/etm.2014.1574. [4]Bernstein MB,Krishnan S,Hodge JW,et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR):a curative approach?[J].Nat Rev Clin Oncol,2016,13(8):516-524.DOI:10.1038/nrclinonc.2016.30. [5]Rudd CE,Taylor A,Schneider H.CD28 and CTLA-4 coreceptor expression and signal transduction[J].Immunol Rev,2009,229(1):12-26.DOI:10.1111/j.1600-065X.2009.00770.x. [6]Fife BT,Bluestone JA.Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J].Immunol Rev,2008,224:166-182.DOI:10.1111/j.1600-065X.2008.00662.x. [7]Sakaguchi S.Regulatory T cells:history and perspective[J]. Methods Mol Biol,2011,707:3-17.DOI:10.1007/978-1-61737-979-6_1. [8]Ji M,Liu Y,Li Q,et al. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations[J].Cancer Biol Ther,2016,17(4):407-413.DOI:10.1080/15384047.2016.1156256. [9]Aggarwal C,Rodriguez-Abreu D,Felip E,et al. Prevalence of PD-L1 expression in patients with non-smallcell lung cancer screened for enrollment in KEYNOTE-001,-010,and-024[J].Ann Oncol,2016,27(6):364.DOI:10.1093/annonc/mdw363. [10]Langer CJ,Gadgeel SM,Borghaei H,et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced,non-squamous non-small-cell lung cancer:a randomised,phase 2 cohort of the open-label KEYNOTE-021 study[J].Lancet Oncol,2016,17(11):1497-1508.DOI:10.1016/S1470-2045(16)30498-3. [11]Gainor JF.Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer[J].J Clin Oncol,2016,34(25):2953-2955.DOI:10.1200/JCO.2016.68.1205. [12]Melosky B,Chu Q,Juergens R,et al. Pointed progress in second-line advanced non-small-cell lung cancer:the rapidly evolving field of checkpoint inhibition[J].J Clin Oncol,2016,34(14):1676-1688.DOI:10.1200/JCO.2015.63.8049. [13]Reck M,Rodríguez-Abreu D,Robinson AG,et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].New Engl J Med,2016,375(19):1823-1833.DOI:10.1056/NEJMoa1606774. [14]Lynch TJ,Bondarenko I,Luft A,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage ⅢB/IV non-small-cell lung cancer:results from a randomized,double-blind,multicenter phase Ⅱ study[J].J Clin Oncol,2012,30(17):2046-2054.DOI:10.1200/JCO.2011.38.4032. [15]Govindan R,Szczesna A,Ahn MJ,et al. Phase Ⅲ trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer[J].J Clin Oncol,2017:O2016717629.DOI:10.1200/JCO.2016.71.7629. [16]Butts C,Socinski MA,Mitchell PL,et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage Ⅲ non-small-cell lung cancer (START):a randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(1):59-68.DOI:10.1016/S1470-2045(13)70510-2. [17]Giaccone G,Bazhenova LA,Nemunaitis J,et al. A phase Ⅲ study of belagenpumatucel-L,an allogeneic tumour cell vaccine,as maintenance therapy for non-small cell lung cancer[J].Eur J Cancer,2015,51(16):2321-2329.DOI:10.1016/j.ejca.2015.07.035. [18]Cuppens K,Vansteenkiste J.Vaccination therapy for non-small-cell lung cancer[J].Cur Opin Oncol,2014,26(2):165-170.DOI:10.1097/CCO.0000000000000052. [19]Dammeijer F,Lievense LA,Veerman GD,et al. Efficacy of tumor vaccines and cellular immunotherapies in non-small-cell lung cancer:a systematic review and meta-analysis[J].J Clin Oncol,2016,34(26):3204-3212.DOI:10.1200/JCO.2015.66.3955. [20]Postow MA,Callahan MK,Barker CA,et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J].New Engl J Med,2012,366(10):925-931.DOI:10.1056/NEJMoa1112824. [21]Panaretakis T,Kepp O,Brockmeier U,et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death[J].EMBO J,2009,28(5):578-590.DOI:10.1038/emboj.2009.1. [22]Lotze MT,Zeh HJ,Rubartelli A,et al. The grateful dead:damage-associated molecular pattern molecules and reduction/oxidation regulate immunity[J].Immunol Rev,2007,220(1):60-81.DOI:10.1111/j.1600-065X.2007.00579.x. [23]Garg AD,Krysko DV,Verfaillie T,et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death[J].EMBO J,2012,31(5):1062-1079.DOI:10.1038/emboj.2011.497. [24]Elliott MR,Chekeni FB,Trampont PC,et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance[J].Nature,2009,461(7261):282-286.DOI:10.1038/nature08296. [25]Apetoh L,Ghiringhelli F,Tesniere A,et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J].Immunol Rev,2007,220(1):47-59.DOI:10.1111/j.1600-065X.2007.00573.x. [26]Apetoh L,Ghiringhelli F,Tesniere A,et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J].Nat Med,2007,13(9):1050-1059.DOI:10.1038/nm1622. [27]Herrera FG,Bourhis J,Coukos G.Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J].CA Cancer J Clin,2017,67(1):65-85.DOI:10.3322/caac.21358. [28]Deloch L,Derer A,Hartmann J,et al. Modern radiotherapy concepts and the impact of radiation on immune activation[J].Front Oncol,2016,6(1):141.DOI:10.3389/fonc.2016.00141. [29]Formenti SC,Demaria S.Combining radiotherapy and cancer immunotherapy:a paradigm shift[J].J Natl Cancer Inst,2013,105(4):256-265.DOI:10.1093/jnci/djs629. [30]Yazdi TM,Schinkelshoek MS,Loof NM,et al. Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer[J].Oncol Immunol,2016,5(12):e1255393.DOI:10.1080/2162402X.2016.1255393. [31]Tang C,Liao Z,Gomez D,et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes[J].Int J Radiat Oncol Biol Phys,2014,89(5):1084-1091.DOI:10.1016/j.ijrobp.2014.04.025. [32]Zhu G.Cellular immunity enhanced after sabr,but decreased afterconventional fractionated radiation therapy of non-small celllung cancer patients[J].Int J Radiat Oncol Biol Phys,2015,93(3S):189.DOI:10.1016/j.ijrobp.2015.07.2196. [33]Chang JY,Senan S,Paul MA,et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-637. [34]Kavanagh BD.Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery:clinically independent but with enduring common themes[J].J Clin Oncol,2014,32(26):2827-2831.DOI:10.1200/JCO.2014.56.7362. [35]Hanna GG,Illidge T.Radiotherapy and immunotherapy combinations in non-small cell lung cancer:a promising future?[J].Clin Oncol,2016,28(11):726-731.DOI:10.1016/j.clon.2016.07.014. [36]Giaccone G,Bazhenova LA,Nemunaitis J,et al. A phase Ⅲ study of belagenpumatucel-L,an allogeneic tumour cell vaccine,as maintenance therapy for non-small cell lung cancer[J].Eur J Cancer,2015,51(16):2321-2329.DOI:10.1016/j.ejca.2015.07.035. [37]Golden EB,Chhabra A,Chachoua A,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial[J].Lancet Oncol,2015,16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6. [38]Qiao M,Jiang T,Ren S,et al. Combination strategies on the basis of immune checkpoint inhibitors in non-small-cell lung cancer:where do we stand?[J].Clin Lung Cancer,2017.DOI:10.1016/j.cllc.2017.06.005. [39]Chen L,Douglass J,Walker AJ,et al. Concurrent immunotherapy and stereotactic radiosurgery for brain metastases is associated with a decreased incidence of new intracranial metastases[J/OL].Int J Radiat Oncol Biol Phys,2015,93(3):E102-E102. [40]Shaverdian N,Lisberg AE,Bornazyan K,et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer:a secondary analysis of the KEYNOTE-001 phase 1 trial[J].Lancet Oncol,2017,18(7):895-903.DOI:10.1016/S1470-2045(17)30380-7. [41]Antonia SJ,Villegas A,Daniel D,et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small-cell lung cancer[J].N Engl J Med,2017,377(20):1919-1929.DOI:10.1056/NEJMoa1709937. [42]von Reibnitz D,Wu AJ,Barker CA,et al. Safety of combining immune checkpoint inhibition and thoracicradiation therapy[J].Int J Radiat Oncol Biol Phys,2016,9(2S):156.DOI:10.1016/j.ijrobp.2016.06.377. [43]Hwang WL,Niemierko A,Hwang KL,et al. Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy[J].JAMA Oncol,2017.DOI:10.1001/jamaoncol.2017.3808. [44]Golden EB,Demaria S,Schiff PB,et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer[J].Cancer Immunol Res,2013,1(6):365-372.DOI:10.1158/2326-6066.CIR-13-0115. [45]Golden EB,Formenti SC.Is tumor (R) ejection by the immune system the"5th R" of radiobiology?[J].Oncoimmunology,2014,3(1):e28133.DOI:10.4161/onci.28133. [46]Golden EB,Chhabra A,Chachoua A,et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours:a proof-of-principle trial[J].Lancet Oncol,2015,16(7):795-803.DOI:10.1016/S1470-2045(15)00054-6. [47]Mclaughlin J,Han G,Schalper KA,et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer[J].JAMA Oncol,2016,2(1):46.DOI:10.1001/jamaoncol.2015.3638. [48]Haikerwal SJ,Hagekyriakou J,Macmanus M,et al. Building immunity to cancer with radiation therapy[J].Cancer Lett,2015,368(2):198-208.DOI:10.1016/j.canlet.2015.01.009. [49]Kalbasi A,June CH,Haas N,et al. Radiation and immunotherapy:a synergistic combination[J].J Clin Invest,2013,123(7):2756-2763.DOI:10.1172/JCI69219. [50]Kiess AP,Wolchok JD,Barker CA,et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab:safety profile and efficacy of combined treatment[J].Int J Radiat Oncol Biol Phys,2015,92(2):368-375.DOI:10.1016/j.ijrobp.2015.01.004. [51]Brahmer JR,Tykodi SS,Chow LQ,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl J Med,2012,366(26):2455-2465.DOI:10.1056/NEJMoa1200694. [52]Topalian SL,Hodi FS,Brahmer JR,et al. Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.DOI:10.1056/NEJMoa1200690.
2018, Vol. 27 
